Polar Capital’s Nektar Therapeutics NKTR Stock Holding History

Polar Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-67,852	Closed	-$60.8M	–	270
2017 Q4	$60.8M	Buy	+67,852	New	+$40.1M	0.63%	38

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Polar Capital's NKTR Position: Q1 2018 in Review

Polar Capital sold out of Nektar Therapeutics (NKTR) in Q1 2018, closing a stake of 67,852 shares — an estimated $60.8M sold.

Polar Capital first reported a position in NKTR in Q4 2017 and held it in 1 quarter. The position peaked at $60.8M in Q4 2017. 358 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

Polar Capital reported no remaining Nektar Therapeutics position as of Q1 2018 after selling out during the quarter.
Polar Capital sold 67,852 Nektar Therapeutics shares in Q1 2018, an estimated $60.8M.
Polar Capital first reported a position in Nektar Therapeutics in Q4 2017 and held it in 1 quarter.
Polar Capital's Nektar Therapeutics position peaked at $60.8M in Q4 2017.
358 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on Polar Capital's 13F filing for Q1 2018, filed 15 May 2018.